Skip to main content Accessibility help
×
Home
  • Print publication year: 2012
  • Online publication date: July 2012

Chapter 9 - Clinical trials management at the site level

Summary

This chapter focuses on drug development for psychiatric as opposed to other central nervous system (CNS) indications such as neurological conditions, pain, and sleep. It provides an overview of how CNS drug development has evolved over its relatively short history of perhaps 50-100 years as well as to provide some sense of how it might evolve in the not-too-distant future. Chlorpromazine and other phenothiazine molecules were synthesized around the turn of the last century and some were initially used to treat pinworm infestation. However, chlorpromazine over the last 50 years has come to play a pivotal role in the modern era of clinical psychopharmacology. CNS drug development principally focused on serotonin selective reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors SNRIs, atypical antipsychotics, and cholinesterase inhibitors. The current development of drugs for Alzheimer's and other neurodegenerative diseases could be a model for how future CNS drug development might proceed.

References

(1999). A word from clinical trials volunteers. Center Watch, 6.
Adams, C. P. and Brantner, V. V. (2006). Estimating the cost of new drug development: is it really 802 million dollars?Health Aff (Millwood), 25 (2), 420–8.
Armstrong, D. (2008). Doctor didn't disclose Glaxo payments, senator says. Wall Street Journal. New York, Dow Jones: A12.
Bain, L. J. (2005). Crossroads in clinical trials. NeuroRx, 2 (3), 525–8.
Bentley, J. P. and Thacker, P. G. (2004). The influence of risk and monetary payment on the research participation decision making process. J Med Ethics, 30 (3), 293–8.
Bodenheimer, T. (2000). Uneasy alliance — clinical investigators and the pharmaceutical industry. New Engl J Med, 342 (20), 1539–44.
Carpenter, W. T., Jr., Appelbaum, P. S., et al. (2003). The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia. Am J Psychiat, 160 (2), 356–62.
DeAngelis, C. D. and Fontanarosa, P. B. (2008). Impugning the integrity of medical science. J Am Med Assoc, 299 (15), 1833–5.
Dorsey, E. R., Vitticore, P., et al. (2006). Financial anatomy of neuroscience research. Ann Neurol, 60 (6), 652–9.
Fava, M., Evins, A. E., et al. (2003). The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom, 72 (3), 115–27.
Getz, K. A., Wenger, J., et al. (2008). Assessing the impact of protocol design changes on clinical trial performance. Am J Ther, 15 (5), 450–7.
Kaiser, J. (2010). Health bill backs evidence-based medicine, new drug studies. Science, 327 (5973), 1562.
Kemp, A. S., Schooler, N. R., et al. (2010). What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?Schizophrenia Bull, 36 (3), 504–9.
Lewis, S. W., Davies, L., et al. (2006). Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess, 10 (17), iii–iv, ix–xi, 1–165.
Lexchin, J. (2011). Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications. Sci Eng Ethics, 1–15.
Michels, R. (1999). Are research ethics bad for our mental health?New Engl J Med, 340 (18), 1427–30.
Moses, H., Dorsey, III, E. R., et al. (2005). Financial anatomy of biomedical research. J Am Med Assoc, 294 (11), 1333–42.
Permuth-Wey, J. and Borenstein, A. R. (2009). Financial remuneration for clinical and behavioral research participation: ethical and practical considerations. Ann Epidemiol, 19 (4), 280–5.
Sismondo, S. (2008). Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemporary Clin Trials, 29 (2), 109–13.
Stiglitz, J. E. and Jayadev, A. (2010). Medicine for tomorrow: some alternative proposals to promote socially beneficial research and development in pharmaceuticals. J Generic Med, 7 (3), 217–26.
Targum, S. D. (2006). Evaluating rater competency for CNS clinical trials. J Clin Psychopharmacol, 26 (3), 308–10.